Stockscreener 앱 받기
26.02
4.27%
-1.16
전일 마감가:
$27.18
열려 있는:
$26.55
하루 거래량:
1.78M
Relative Volume:
0.65
시가총액:
$1.42B
수익:
$27.10M
순이익/손실:
$-24.31M
주가수익비율:
-31.35
EPS:
-0.83
순현금흐름:
$-33.33M
1주 성능:
-3.24%
1개월 성능:
+343.27%
6개월 성능:
+86.66%
1년 성능:
+81.45%
1일 변동 폭
$25.59
$27.12
1주일 범위
$25.59
$31.44
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
CAPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
26.02 | 1.48B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering - Sidley Austin
Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on CAPR, Raises Price Target | CAPR Stock News - GuruFocus
What Does the Market Think About Capricor Therapeutics Inc? - Benzinga
Biotech Stocks To Add to Your WatchlistDecember 5th - MarketBeat
A strong week for data readouts: Clinical Report - BioCentury
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial - Indian Pharma Post
Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Oppenheimer Maintains Capricor Therapeutics (CAPR) Outperform Recommendation - Nasdaq
Oppenheimer raises Capricor Therapeutics price target to $54 on positive trial data - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.8%What's Next? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Oppenheimer Raises Capricor Therapeutics (CAPR) Price Target to $54 | CAPR Stock News - GuruFocus
Oppenheimer Adjusts Capricor Therapeutics PT to $54 From $22, Maintains Outperform Rating - marketscreener.com
Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes - Sahm
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
Capricor Therapeutics launches proposed public offering of common stock - MSN
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints - MSN
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpShould You Buy? - MarketBeat
Capricor Therapeutics (CAPR): Assessing Valuation After a Strong Multi-Week Share Price Rally - Sahm
How Recent Developments Are Rewriting the Story for Capricor Therapeutics - Yahoo Finance
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular DystrophySlideshow (NASDAQ:CAPR) 2025-12-05 - Seeking Alpha
Capricor Therapeutics Announces $150 Million Public Offering - TradingView
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - The Globe and Mail
Capricor Therapeutics (CAPR) Stock :Prices $150M Offering for Next-Gen DMD Treatment Development - parameter.io
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownShould You Sell? - MarketBeat
Capricor Therapeutics sets pricing of $150 mln public offering of shares - marketscreener.com
Published on: 2025-12-05 06:37:44 - Newser
Capricor Therapeutics (CAPR) Surges After Pricing $150M Stock Of - GuruFocus
CAPR Collaborates with Managers for Successful Offering - GuruFocus
Can Capricor Therapeutics Inc. stock continue upward trendWeekly Profit Report & Consistent Return Strategy Ideas - Newser
Capricor Therapeutics Prices $150 Million Common Stock Offering; Shares Up Pre-Bell - marketscreener.com
Capricor Therapeutics prices public offering at $25 per share - Investing.com
Capricor Therapeutics prices public offering at $25 per share By Investing.com - Investing.com UK
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock - marketscreener.com
Why Capricor Therapeutics Inc. (4LN2) stock stays undervaluedMarket Rally & Weekly Stock Performance Updates - Newser
Is Capricor Therapeutics Still Attractive After Its 375% Surge in 2025? - simplywall.st
Geode Capital Management LLC Acquires 61,701 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Capricor Therapeutics Inc. stock remains a top recommendationWeekly Trend Summary & Verified Momentum Stock Ideas - Newser
What insider trading reveals about Capricor Therapeutics Inc. stockJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Inside Biotech: Capricor’s Duchenne results ignite a 500% surge — and an immediate equity raise - Proactive financial news
Capricor Therapeutics launches common stock offering By Investing.com - Investing.com South Africa
Maxim Group Maintains Capricor Therapeutics (CAPR) Buy Recommendation - Nasdaq
CAPR Stock Update: Piper Sandler and Oppenheimer Lead Offering - GuruFocus
Small Cap Stocks To ResearchDecember 3rd - MarketBeat
Capricor Therapeutics (CAPR) Launches Public Offering Amid Marke - GuruFocus
Capricor Therapeutics announces common stock offering, no amount given - TipRanks
Capricor Therapeutics Launches Proposed Public Stock Offering - marketscreener.com
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):